For almost two decades, a Wisconsin resident named Tim Friede has been exposing himself to snake venom by self-injecting small amounts and receiving bites in order to develop resistance. His extreme practice began out of fascination and curiosity about reptiles and venomous creatures. Recently, scientists have started studying his blood to develop a new type of antivenom. According to the World Health Organization, snakebites cause around 110,000 deaths each year, especially in areas with limited medical resources. Traditional antivenoms are expensive, species-specific, and often result in allergic reactions because they are made from animal antibodies. A recent study published in the journal Cell announced that researchers, including Columbia University’s Peter Kwong, discovered two rare antibodies in Friede’s blood that can neutralize venom from several snake species, including black mambas and cobras.

Researchers believe Friede’s antibodies could lead to a universal antivenom that is safer and more affordable. The experimental treatment has shown efficacy in mice, but human trials are still years away. While the new antivenom does not yet work on all snakes—such as vipers—experts like Nicholas Casewell from the Liverpool School of Tropical Medicine call the results promising. Friede is now working for Centivax, a biotechnology firm that supports the ongoing research. Despite the scientific interest, he has warned the public not to replicate his dangerous experiments, which have resulted in serious injuries, including the loss of part of a finger. Experts emphasize that while Friede’s antibodies are extraordinary, professional research remains the only safe and ethical path toward medical advancement.